# RANI catalysts: Rani Therapeutics Holdings, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/rani/catalysts

> Rani Therapeutics Holdings, Inc. (RANI) has no upcoming catalysts in this calendar. The latest recorded is the Rani Therapeutics Holdings, Inc. earnings report, November 9, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Rani Therapeutics Holdings, Inc. |
| Ticker | RANI (Nasdaq) |
| SEC CIK | 1856725 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/rani |

## Cash runway

Cash $3.6M as of 2026-09-30; quarterly burn $7.8M; about 1.4 months of runway at that rate (XBRL company facts, accession 0001193125-26-453872).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Feb 2024 | [RT-111 topline data readout](https://sec-api.dev/pdufa/rt-111) | RANI | inflammatory conditions | completed, positive | "In February 2024, we announced positive topline results from a Phase 1 study of RT-111, which is being developed for the potential treatment of inflammatory conditions." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1856725/000119312526126417/rani-20251231.htm)) |
| November 14, 2024 | [Rani Therapeutics Holdings, Inc. earnings report](https://sec-api.dev/companies/rani/catalysts) | RANI |  | completed | "Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1856725/000095017024126753/rani-ex99_1.htm)) |
| March 31, 2025 | [Rani Therapeutics Holdings, Inc. earnings report](https://sec-api.dev/companies/rani/catalysts) | RANI |  | completed | "Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1856725/000095017025047701/rani-ex99_1.htm)) |
| May 13, 2025 | [Rani Therapeutics Holdings, Inc. earnings report](https://sec-api.dev/companies/rani/catalysts) | RANI |  | completed | "Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1856725/000095017025070344/rani-ex99_1.htm)) |
| August 7, 2025 | [Rani Therapeutics Holdings, Inc. earnings report](https://sec-api.dev/companies/rani/catalysts) | RANI |  | completed | "Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1856725/000095017025104998/rani-ex99_1.htm)) |
| late 2025 | [RT-114 trial start](https://sec-api.dev/pdufa/rt-114) | RANI | obesity | scheduled | "Initiation of Phase 1 clinical trial of RT-114 for the treatment of obesity expected in the second half of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1856725/000095017025104998/rani-ex99_1.htm)) |
| November 6, 2025 | [Rani Therapeutics Holdings, Inc. earnings report](https://sec-api.dev/companies/rani/catalysts) | RANI |  | completed | "Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1856725/000119312525269722/rani-ex99_1.htm)) |
| Dec 2025 | [RT-114 trial start](https://sec-api.dev/pdufa/rt-114) | RANI |  | completed | "In December 2025, Rani initiated a Phase 1 clinical trial to evaluate the safety, tolerability, bioavailability and pharmacokinetics and pharmacodynamics of single and multiple doses of RT-114." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1856725/000119312526126240/rani-ex99_1.htm)) |
| March 26, 2026 | [Rani Therapeutics Holdings, Inc. earnings report](https://sec-api.dev/companies/rani/catalysts) | RANI |  | completed | "Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1856725/000119312526126240/rani-ex99_1.htm)) |
| May 11, 2026 | [Rani Therapeutics Holdings, Inc. earnings report](https://sec-api.dev/companies/rani/catalysts) | RANI |  | completed | "Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1856725/000119312526226691/rani-ex99_1.htm)) |
| July 15, 2026 | [RT-114 interim data readout](https://sec-api.dev/pdufa/rt-114) | RANI |  | completed, positive | "On July 15, 2026, we announced positive initial data from the single-dose, open-label Phase 1a portion of our ongoing Phase 1 clinical trial of RT-114." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1856725/000119312526453872/rani-20260930.htm)) |
| August 13, 2026 | [Rani Therapeutics Holdings, Inc. earnings report](https://sec-api.dev/companies/rani/catalysts) | RANI |  | completed | "Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1856725/000119312526349197/rani-ex99_1.htm)) |
| August 13, 2026 | [RT-114 trial start](https://sec-api.dev/pdufa/rt-114) | RANI |  | completed | "Rani also announced today that the first participants have been dosed in the Phase 1a study expansion cohort of RT-114, an orally administered RaniPill Capsule delivering PG-102, a" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1856725/000119312526349197/rani-ex99_1.htm)) |
| late 2026 | [RaniPill (RT-116) trial start](https://sec-api.dev/pdufa/rt-116) | RANI | obesity | scheduled | "GLP-1/GLP-2 dual agonist being developed by ProGen Co., Ltd. The study was expanded to enroll fifteen additional healthy volunteers to provide a comprehensive pharmacokinetic dataset for the RaniPill® HC as Rani moves toward initiating a Phase 1b repeat-dose study in patients with obesity by the end of 2026, with data anticipated in 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1856725/000119312526349197/rani-ex99_1.htm)) |
| November 9, 2026 | [Rani Therapeutics Holdings, Inc. earnings report](https://sec-api.dev/companies/rani/catalysts) | RANI |  | completed | "Rani Therapeutics Reports Third Quarter 2026 Financial Results; Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1856725/000119312526453804/rani-ex99_1.htm)) |

## Drugs

- [RT-111](https://sec-api.dev/pdufa/rt-111): inflammatory conditions
- [RT-114](https://sec-api.dev/pdufa/rt-114): obesity
- [RaniPill (RT-116)](https://sec-api.dev/pdufa/rt-116): obesity

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/rani/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "RANI catalysts: Rani Therapeutics Holdings, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/rani/catalysts

```bibtex
@misc{secapidev_companies_rani_catalysts_20261116,
  title        = {RANI catalysts: Rani Therapeutics Holdings, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/rani/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_rani_catalysts_20261116","title":"RANI catalysts: Rani Therapeutics Holdings, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/rani/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
